dr. monk on the fda approval of maintenance rucaparib in ovarian cancer
Published 6 years ago • 274 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
0:16
copy of dr. monk on the fda approval of maintenance rucaparib in ovarian cancer
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
5:18
rucaparib for ovarian cancer
-
0:40
dr. willmott on fda approval of maintenance olaparib in ovarian cancer
-
1:10
dr. o'malley on fda approval of maintenance rucaparib in ovarian cancer
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
0:53
dr. monk on combination therapies in patients with ovarian cancer
-
6:12
rucaparib for recurrent ovarian cancer
-
1:48
dr. monk on trial endpoints for ovarian cancer agents
-
1:42
dr. ledermann on rucaparib maintenance in ovarian cancer
-
1:20
dr. monk on the forward i trial in ovarian cancer
-
1:07
monk: dr. monk on the significance of bevacizumab in cervical cancer
-
1:15
dr. birrer on fda approval of rucaparib in ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
1:54
dr. o’malley on maintenance rucaparib in non-brca hrr-mutated in ovarian cancer
-
11:05
parp inhibitors in recurrent ovarian cancer
-
2:43
an introduction to the discussion of ovarian cancer